- Previous Close
0.9196 - Open
0.8800 - Bid 0.8952 x 100
- Ask 0.9352 x 100
- Day's Range
0.8592 - 0.9200 - 52 Week Range
0.8100 - 4.1900 - Volume
110,042 - Avg. Volume
130,808 - Market Cap (intraday)
21.759M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
www.enlivex.comRecent News: ENLV
View More
Performance Overview: ENLV
Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENLV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENLV
View MoreValuation Measures
Market Cap
21.52M
Enterprise Value
-1.44M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.91
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.10%
Return on Equity (ttm)
-55.95%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.01M
Diluted EPS (ttm)
-0.7300
Balance Sheet and Cash Flow
Total Cash (mrq)
23.5M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.24M